VA-LEPTON/SATCUBE
9.3.2021 15:02:11 CET | Business Wire | Press release
Lepton Global Solutions (www.leptonglobal.com ), a Kymeta company, and leading provider of satellite-based customized turn-key communications solutions and services, announced today a strategic partnership with Satcube (www.satcube.com ). The partnership will add Satcube’s class of extremely small VSAT terminals to the company’s global satellite network, which is engineered to support terminal aperture sizes down to 45cm. In turn, Lepton Global Solutions will offer Satcube Ku terminals globally as a comms-on-the-pause (COTP) solution that are complementary with the Kymeta™ u8 comms-on-the-move (COTM) offering, running both on the same frequencies with easily transportable and operated hardware.
Together, Lepton Global Solutions and Satcube are challenging the traditional ways satellite communications are delivered and consumed through highly automated, easily transportable products low in size, weight, and power. The goal of the partnership is to deliver world-class technology and services to defense, public safety, and commercial customers globally. Both the Satcube and the u8 terminal are designed to fulfill tactical, easy-to-use operational requirements. Their differing form factors and capability sets address differing applications of users on the move.
“Most commercial satellite service networks are designed for larger aperture antennas that operate at broadside, which means that smaller, flat panel terminals like the Satcube and u8 are not globally supported,” said Isabel LeBoutillier, Vice President of Kymeta Connect and Government Programs. “Our network has been built from the ground up to accommodate the technical requirements of this newer class of extremely small, flat-panel VSAT terminals. The partnership with Satcube will allow us to deliver superior connectivity options for more applications to our mobile customers.”
“This partnership will allow our companies to better meet the requirements of our complementary customers and provide solutions that fit the needs of a broader audience,” said Jakob Kallmer, Satcube CEO and founder. “Our relationship with Lepton will enable Satcube to provide a more seamless and reliable connectivity experience to our customers globally, and we couldn’t be more thrilled to be working together.”
Satcube Ku is an all-in-one compact carry-on satellite terminal with a flat antenna the size of a large laptop. The terminal enables users to create an easy-to-use Wi-Fi hotspot and receive high-speed broadband connection in less than one minute to execute critical, on the spot work assignments and communications.
Lepton Global Solutions and Satcube leverage Kymeta Broadband , which is the first satellite service designed to serve the unique characteristics of flat panel antennas used in land-mobile applications. Built from the ground up and software defined for disadvantaged terminals and antennas, the service ensures that customers stay connected without latency or throughput challenges. Customers receive capacity through a managed network that aggregates multiple satellite providers and hundreds of operators for global coverage.
Lepton’s network offering for these terminals includes global customized CIR plans as well as Kymeta Broadband’s satellite 5x2 MIR and hybrid satellite-cellular options. Service may be purchased for individual terminals or shared among multiple terminals.
About Lepton Global Solutions:
Lepton Global Solutions, a Kymeta company, specializes in the engineering and delivery of customized, yet cost-effective, turnkey satellite communications solutions to commercial and government customers. Lepton’s end-to-end solutions, which go beyond managed satellite services to include VSAT equipment installation, 24×7 technical support and customized back end IT infrastructure, are tailored to meet customer-specific needs.
Lepton is headquartered outside of Washington, D.C. in Tysons Corner, Virginia.
For additional information, please visit www.leptonglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005025/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom